Fine‐Tuning Lipid‐Coated Porous Silicon Nanoparticles for siRNA Delivery
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202503238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Pouya Dehghankelishadi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: RNA, Small Interfering, Silicon, Nanoparticles, Lipids. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Melbourne Centre for Nanofabrication, Australian National Fabrication Facility, National Health and Medical Research Council.
Abstract (Originalsprache)
Small interfering RNA (siRNA) is a growing treatment avenue for cancer patients. However, formulating siRNA to achieve high tumoral delivery efficiency is challenging. Among various formulation strategies, porous silicon nanoparticles (pSiNPs) are unique due to the versatile nanoengineering options. This study builds on and aims to further refine two successful strategies previously developed for pSiNPs‐based siRNA delivery systems: calcium silicate sealing and lipid coating. The application of alternative lipid composition based on ionisable lipids (dilinoleyl‐methyl‐4‐dimethylaminobutyrate (MC3)) is investigated and head‐to‐head compared with previously developed coatings based on quaternary ammonium lipids (1,2‐dioleoyl‐3‐trimethylammonium‐propane (DOTAP)) associated with potential in vivo safety concerns. While the MC3 formulation underperforms compared to the DOTAP‐based formulation in terms of siRNA loading and in vitro cellular association, comparable lysosomal escape rate and acceptable levels of siRNA transfection are observed. In vivo biodistribution of formulations is compared head‐to‐head, with higher tumor accumulation observed for the MC3 formulation in an orthotopic breast cancer murine model. Formulations are well‐tolerated at a 20 mg/kg dose. As another approach for refinement of the formulation for siRNA delivery, the lipid‐coated pSiNPs are functionalized using an anti‐human desmoglein‐2 monoclonal antibody (aDSG2) to achieve better transfection efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
- Centre For Cancer Biology, University of South Australia and SA Pathology, Adelaide, South Australia, Australia.
- Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
- Melbourne Centre for Nanofabrication, Victorian Node of the Australian National Fabrication Facility, Clayton, Victoria, Australia.
ORCID-Profile: Nicolas H Voelcker
Förderung
- Melbourne Centre for Nanofabrication
- Australian National Fabrication Facility
- National Health and Medical Research Council
Zitieren
APA
Dehghankelishadi, P., Badiee, P., Qiao, S., Yao, Q., Cockshell, M. P., Bonder, C. S., & Voelcker, N. H. (2025). Fine‐Tuning Lipid‐Coated Porous Silicon Nanoparticles for siRNA Delivery. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503238
Vancouver
Dehghankelishadi P, Badiee P, Qiao S, Yao Q, Cockshell MP, Bonder CS, et al. Fine‐Tuning Lipid‐Coated Porous Silicon Nanoparticles for siRNA Delivery. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202503238
BibTeX
@article{Dehghankelishadi2025,
author = {Dehghankelishadi, Pouya and Badiee, Parisa and Qiao, Shiying and Yao, Qiuyang and Cockshell, Michaelia P and Bonder, Claudine S and Voelcker, Nicolas H},
title = {Fine‐Tuning Lipid‐Coated Porous Silicon Nanoparticles for siRNA Delivery},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202503238}
}
EUVIMED